Gregory Lesinski, Associate Director of Basic Research at Winship Cancer Institute of Emory University, shared a post on LinkedIn:
“Kudos to Thatcher Heumann for leading this ambitious phase II cholangiocarcinoma immunotherapy clinical trial! Major collaborative effort with The National Institutes of Health, Winship Cancer Institute of Emory University, Vanderbilt University, The Johns Hopkins University, Cholangiocarcinoma Foundation and more!”
Chrystal Paulos, Professor and Co-leader of the Cancer Immunology Program at Winship Cancer Institute of Emory University, shared this post, adding:
“Reposting with huge congratulations to Thatcher Heumann for leading this important phase II cholangiocarcinoma immunotherapy trial. Cheers to Gregory Lesinski for his leadership/sustained collaborations to help drive the work.
Terrific example of multi-institutional team science across Winship, Vanderbilt, Johns Hopkins, NIH, the Cholangiocarcinoma Foundation, and many others. Kudos to the entire team for pushing the field forward for patients.”
Title: A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without cobimetinib in previously-treated unresectable biliary tract cancer
Authors: Thatcher Ross Heumann, Jiayun Lu, Hao Wang, Mitch Phelps, Qingfeng Zhu, Robert Anders, Sarah Mitchell, James Leatherman, Nicole Abbott, Kyeongmin Kim, Teresa Imhof, Zhiliang Xie, Alexandra Partey, Daneng Li, Paul Raymond Kunk, Renuka V. Iyer, Farshid Dayyani, Lionel Aurelien Kankeu, Aparna Kalyan, Olumide B. Gbolahan, Milind M. Javle, S. Lindsey Davis, Vaia Florou, Kristen Spencer, Elad Sharon, Mark Yarchoan, Gregory B. Lesinski, Nilofer Saba Aza
Read the Full Article.
